Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
Displaying: 91 trials in your specialties ()
View trials across your selected specialties

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    T Cell Lymphoma
View Full Trial
INTERVENTION

Drug: Tenalisib, Drug: Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Brief Summary

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Colorectal Cancer
View Full Trial
INTERVENTION

Drug: Oral CC - 486, Drug: Romidepsin, Drug: MK - 3475

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Brief Summary

This study is being done to test the safety and effectiveness of the combination of intravenous (IV) romidepsin and/or oral 5-azacitidine with IV MK-3475 in people with microsatellite stable (MSS) advanced colorectal cancer.

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Recurrent Bladder Carcinoma, Glioma, Hematopoietic and Lymphoid C...
View Full Trial
INTERVENTION

Other: Pharmacological Study, Drug: Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Brief Summary

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Lymphoma, Relapsed/Refractory T-cell Lymphomas
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: Bortezomib, Drug: duvelisib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Stanford University Medical Center, Stanford, California, United States

Brief Summary

The purpose of this study is to test the safety of a study drug called duvelisib.

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Non-Hodgkin's Lymphoma, Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: Lenalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Saint Francis/Mount Sinai Regional Cancer Center, Hartford, Connecticut, United States

Brief Summary

The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Hiv
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: 3BNC117, Drug: Antiretrovirals

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Department of Infectious Diseases, Aalborg, Denmark

Brief Summary

To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent HIV-1 reservoir in treatment naïve HIV-1 patients initiating antiretroviral therapy (ART)

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic ...
View Full Trial
INTERVENTION

Drug: Ro-CHOEP-21 (PHASE I), Drug: Ro-CHOEP-21 (PHASE II)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy

Brief Summary

This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin will be used for the subsequent phase II study. 2. A phase II study to evaluate the efficacy (response rate, progression free survival and overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy including SCT.

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    T Cell Non-Hodgkin Lymphoma
View Full Trial
INTERVENTION

Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Moffitt Cancer Center, Tampa, Florida, United States

Brief Summary

The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgki...
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: Gemcitabine, Drug: Oxaliplatin, Drug: Dexamethasone, Drug: Pegfilgrastim

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Chicago, Chicago, Illinois, United States

Brief Summary

The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD. GemOxD is a routine treatment for certain types of lymphoma, and involves the administration of three drugs: gemcitabine, oxaliplatin, and dexamethasone. In addition to finding the maximum tolerated dose of romidepsin, the investigators want to look at the side effects of these drugs when given together, as well as how the lymphoma responds to this treatment.

A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

  • Status
    Not yet recruiting
  • Phase
    Phase 1
  • Condition
    Relapsed/Refractory T-cell Malignancies, Cutaneous T-Cell Lymphom...
View Full Trial
INTERVENTION

Drug: Romidepsin, Drug: Lenalidomide, Drug: 5-azacitidine, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Brief Summary

Background: - Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US - Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimens, that produce long-term progression-free survival in about 30% of these cases - Patients with relapsed/refractory (R/R) TCM have very poor prognosis with median overall survival of less than 1 year. Treatment options for R/R TCM are very few and of limited efficacy, thus novel treatment strategies are urgently needed. - Mutations in epigenetic regulators are common in aggressive TCMs and standard treatment with histone deacetylase inhibitors (HDACi) such as romidepsin show modest clinical activity with single agent the overall response (ORR) around 25% - Combination of romidepsin and 5-azacitidine (hypomethylating agents) was synergistic in preclinical models, and has demonstrated high clinical activity with an ORR of 79% - Many TCMs rely on The Ikaros-dependent NF-kB/IRF4 signaling pathway to maintain proliferation, which is why lenalidomide, which induces degradation of Ikaros and downregulates IRF4, has single agent activity in R/R TCM with ORR of 26% to 42%, depending on the subtype. - Lenalidomide synergizes with romidepsin and enhances tumor cell death in TCM cell lines, predicting that the addition of lenalidomide to the established romidepsin/ CC-486 (5- azacitidine) combination will further improve efficacy. Objectives: To determine the safety and toxicity profile and the maximum tolerated dose (MTD) of the four-drug combination of CC-486 (5-azacitidine), romidepsin, lenalidomide and dexamethasone in patients with TCM Eligibility: - Refractory/relapsed TCM defined as follows: - Patients with systemic disease - Have received at least one line of prior therapy - Must have received brentuximab vedotin if the disease is anaplastic large cell lymphoma or CD30-positive cutaneous T-cell lymphoma - Age greater than or equal to 18 years of age - ECOG performance status of less than or equal to 2 (or less than or equal to 3 if decrease is due to the disease) - Histologically or cytologically confirmed relapsed and/or refractory mature TCM - Adequate organ and marrow function Design: - Open-label, single-center, uncontrolled Phase 1 study - '3 + 3' design will be used to determine the MTD of dose-escalated lenalidomide with fixed dose of romidepsin and CC-486 (5-azacitidine) - An expansion cohort of 9 patients will be evaluated at the MTD - Maximum 6 cycles (21-day cycle) of combination therapy - To explore all dose levels, including further evaluation in a dose expansion cohort, the accrual ceiling will be set at 30 patients